LumaVida Women’s Health Institute Business Plan — Financial Plan

This section and the four that follow present a complete, internally consistent financial model. The sponsor brief provides an illustrative frame, a flagship generating ~R16.5 million of revenue and ~R4.5 million of clinic EBITDA in Year 1, and a national network of nine clinics reaching ~R180 million of revenue at a ~25% EBITDA margin (~R45 million) by Year 5, funded by an initial R25 million. This model builds a transparent, year-by-year plan consistent with those figures: it derives revenue from an explicit clinic-by-clinic rollout and maturation, applies a margin that reaches the 25% target, and independently derives every line below EBITDA, the (light) depreciation, full cash interest on drawn debt, and 27% tax with assessed-loss carry-forward. The balance sheet is constructed to tie in every year, and the cash flow reconciles to the movement in cash.

Key performance indicators to monitor

Lenders and equity investors will track a defined set of indicators through the rollout. The dashboard below sets out the metrics, their purpose, and the modelled trajectory.

Indicator	What it signals	Modelled trajectory
Clinics open & network maturity	Rollout & ramp progress	1 → 9 clinics; 9% → 100% mature
OB/GYNs recruited	The binding constraint	Toward 36, metros first
Wellness members	Recurring-revenue traction	Toward 10,000 (ambitious)
EBITDA margin	Operating leverage	21% → 25% (into target)
DSCR	Debt serviceability	Comfortable once debt drawn (Year 2+)
Cash balance	Liquidity through the build	Positive; thins to ~R6m in Year 5
Phase-2 follow-on	Funding the national vision	Required in Years 2–3
ROCE	Capital efficiency	Strong — a capital-light model

Financial performance at a glance

The dashboard below summarises the model’s headline outputs across the five-year projection: a capital-light network that is profitable from Year 1 and scales to the sponsor’s Year-5 targets as the nine clinics open and mature.

Metric	Year 1	Year 3	Year 5
Revenue (R m)	17	96	180
EBITDA (R m)	4	23	45
EBITDA margin	21.0%	23.5%	25.0%
Net profit (R m)	1	7	19
Clinics open	1	5	9
Members	944	5,333	10,000
DSCR (x)	n/a	5.25x	1.55x
ROCE	4.3%	8.2%	19.0%

Revenue by service line at maturity

The revenue base is diversified across five service lines, so that high-volume consultations are balanced by higher-value surgery and fertility work and the recurring membership. The breakdown below applies the target service mix to the Year-5 revenue of R180m.

Service line	Share	Year-5 revenue (R m)
Specialist consultations	44%	79
Diagnostics & ultrasound	16%	29
Surgical procedures (hospital partnerships)	22%	40
Fertility & reproductive medicine	8%	14
Membership & corporate wellness	10%	18
Total	100%	180

Figure 18. *Revenue mix at maturity by service line*

Key modelling assumptions

Assumption	Value	Basis
Clinics	9 (one per province)	Phased 1/2/2/2/2 over Years 1–5
Mature revenue per clinic	~R21m/year	Blended across five service lines
Clinic ramp	~82% / 96% / 100% by age	~3-year maturation; fast (outpatient)
Year-5 EBITDA margin	~25%	Sponsor target; profitable from Year 1
Depreciation	Straight-line by component	Fit-out/equipment 8yr; platform 5yr
Seed / full programme	R25m / ~R132m	Seed is Phase 1; follow-on required
External funding	Equity R85m / Debt R35m	~R120m; rest reinvested cash
Cost of debt	11.5%	~ prime + 100bps (healthcare)
Working capital	~9% of revenue	Medical-aid receivables
Corporate tax / exit	27% / 9x EV/EBITDA	Loss carry-forward; healthcare comparable

Sources and uses

The immediate R25 million seed and its use of funds are set out below, alongside the full national-programme funding picture that the plan ultimately requires.

Phase-1 seed (uses)	R m	Full programme (sources)	R m
Clinic fit-out (flagship)	8	Equity (incl. R25m seed)	85
Medical equipment (flagship)	5	Development / equipment debt	35
Technology platform	3	Reinvested operating cash	~12
Recruitment & pre-opening	4
Launch marketing	3
Working capital	2
Total seed	25	Total programme	~132

Figure 19. *External funding structure — full programme*

Analyst flagThe R25m seed funds Phase 1 — the national programme needs ~R132m

This is the single most important point in the financial plan. The R25 million launches the flagship and the platform; it does not fund the national network. Building nine clinics requires roughly R132 million of capital over five years, about R120 million of external funding (approximately R85 million equity, including the seed, and R35 million of development finance) plus around R12 million of reinvested operating cash. The capital-light model self-funds a meaningful share, but a substantial Phase-2 follow-on raise is integral to the plan and must be underwritten from the outset. Investors backing the seed are funding proof-of-concept; investors backing the vision are underwriting the full programme.

Alignment with impact and development-finance mandates

The transaction is structured for a blend of equity, development finance and impact-health capital, and its features map onto their mandates. LumaVida expands access to specialist women’s health, improves maternal outcomes, screens at scale for cervical and other cancers, and creates over 200 skilled jobs, core objectives for development-finance and impact investors. For commercial lenders, the equipped clinics and the recurring membership base provide security and predictable cash. The health-impact case and the financial case reinforce one another.

Healthcare peer economics — a reality check

South African private-healthcare operators discipline the plan’s assumptions. The hospital groups (Mediclinic, Netcare, Life) show that specialist healthcare is attractive but regulated and specialist-dependent; the fertility groups (Vitalab, Medfem, Cape Fertility) show both the demand for and the scarcity of reproductive medicine. LumaVida’s integrated, branded, capital-light women’s-health model is differentiated from all of them, but it inherits the sector’s central lesson: clinical capacity, not capital, is the constraint.

Dimension	Hospital groups	Fertility clinics	LumaVida
Model	Multi-specialty hospitals	Single-service fertility	Integrated women’s lifecycle
Capital	Very heavy (theatres, beds)	Moderate (labs)	Light (outpatient; partners)
Constraint	Beds, specialists, tariffs	Subspecialists, embryology	OB/GYN & fertility supply
Relevance	Partner & tariff read	Fertility benchmark	First integrated national brand